 A multiple-dose, double-blind, randomized, four-week, three-treatment, parallel study in which 66 healthy adult subjects will receive 6 capsulesd, administered as a dose of 1.3 gd eicosapentaenoic acid EPAdocosahexaenoic acid DHA in fish oil ethyl ester EE, or fish oil triglyceride TG or krill oil for a total of 4 weeks. The objective of the study is to compare the oral bioavailability of EPADHA in total plasma across the three formulations at the end of the 4 week study. 